1Loftsson T, Stefánsson E. Cyclodextrins in eye drop formulations: enhanced topical delivery of corticostemids to the eye [ J ]. Acta Ophthalmol Scand, 2002, 80(2):144- 150.
2Sigurdsson HH, Stefánsson E, Gudmrmdsdottir E, et al. Cyelodextrin formulation of dorzolamide and its distribution in the eye after topical administration[J]. J Control Release, 2005, 102( 1 ) :255 - 262.
3Gudmundsdottir E, Stefánsson E, Bjarnadottir G, et al. Methazolamide 1% in eyelodextrin solution lowers IOP in human ocular hypertension[J]. Invest Ophthalmol Vis Sci , 2000, 41 ( 11 ): 3552 -3554.
4Stefánsson E, Loftsson T. Cydodextrins in eye drop formulations[J].J lacl Phenom Macro, 2002, 44(1 -4):23 - 27,
5Loftsson T, Másson M. Cyclodextrins in topical drug formulations:theory and practice[J], Int J Pharm, 2001, 225(1/2),15- 30.
6Andrew RB, Ian GT, Nigel MD. Considerations in the use of hydroxypropyl-β-cyclodextrin in the formulation of aqueous ophthalmic solutions of hydrocortisone[J]. Eur J Pharm, 2000, 50(2) :237 - 244.
7Loftsson T, Másson M, Sigurdsson HH, Cyclodextrins and drug permeability through semi-permeable cellophane membranes [J]. Int J Pharm, 2002, 232(1/2):35 -43.
8Wang S, Li D, Ito Y, et al. Bioavailability and anticatarant effects of a topical cedar drug delivery system containing disulfiram and hydroxypropyl-beta-cyclodextrin on selenite-treated rats [ J]. Curr Eye Res, 2004, 29(1):51-58.
9Wang S, Li D, Kto Y, et al. An ocular drug delivery system containing zinc diethyldithiocarbamate and HP-β-CD inclusion complex-corneal permeability, anti-cataract effects and mechanism studies[J].J Pharm Pharmacol, 2004, 56(10) :1251 - 1257.
10Knapp S, Bertelmann E, Hartmann C, et al. Intraocular availability of topically applied mycophenolate mofetil in rabbits [ J ]. J Ocul Pharmcol Ther, 2003, 19(2):181- 192.
